These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30286256)

  • 1. A new approach to pharmaceutical pricing based on patients' willingness to pay.
    Rahimi F; Rasekh HR; Abbasian E; Peiravian F
    Trop Med Int Health; 2018 Dec; 23(12):1326-1331. PubMed ID: 30286256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value-based differential pricing: efficient prices for drugs in a global context.
    Danzon P; Towse A; Mestre-Ferrandiz J
    Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
    Mestre-Ferrandiz J; Zozaya N; Alcalá B; Hidalgo-Vega Á
    Pharmacoeconomics; 2018 Dec; 36(12):1407-1420. PubMed ID: 30198061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of external price referencing of pharmaceuticals in Middle East countries.
    Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of studies reporting actual prices for medicines.
    Mardetko N; Kos M; Vogler S
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):159-179. PubMed ID: 30468097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Price Models for Multi-indication Drugs: A Systematic Review.
    Campillo-Artero C; Puig-Junoy J; Segú-Tolsa JL; Trapero-Bertran M
    Appl Health Econ Health Policy; 2020 Feb; 18(1):47-56. PubMed ID: 31523756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept.
    Wettstein DJ; Boes S
    BMC Health Serv Res; 2021 Mar; 21(1):234. PubMed ID: 33726735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient preferences and willingness-to-pay for ADHD treatment with stimulants using discrete choice experiment (DCE) in Sweden, Denmark and Norway.
    Glenngård AH; Hjelmgren J; Thomsen PH; Tvedten T
    Nord J Psychiatry; 2013 Oct; 67(5):351-9. PubMed ID: 23245636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International trade and determinants of price differentials of insulin medicine.
    Helble M; Aizawa T
    Health Policy Plan; 2017 Feb; 32(1):1-10. PubMed ID: 27346189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comment on the implications of external price referencing of pharmaceuticals in Middle East countries.
    Carapinha JL
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):11-4. PubMed ID: 26707161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consumer food choices: the role of price and pricing strategies.
    Steenhuis IH; Waterlander WE; de Mul A
    Public Health Nutr; 2011 Dec; 14(12):2220-6. PubMed ID: 21752312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients' preferences and willingness-to-pay for disease-modifying therapies.
    Frost N; Freeman J; Brixner D; Mort J; Clem J; Ngorsuraches S
    Mult Scler Relat Disord; 2019 Oct; 35():55-60. PubMed ID: 31323483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
    Barth J; Hammerschmidt T; Vollmar J; Bierbaum M; Schöffski O
    Gesundheitswesen; 2014 Apr; 76(4):e7-e13. PubMed ID: 24081570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Approaches to Drug Pricing.
    Kang SY; Bai G; DiStefano MJ; Socal MP; Yehia F; Anderson GF
    Annu Rev Public Health; 2020 Apr; 41():499-512. PubMed ID: 31874070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pricing medicines: theory and practice, challenges and opportunities.
    Gregson N; Sparrowhawk K; Mauskopf J; Paul J
    Nat Rev Drug Discov; 2005 Feb; 4(2):121-30. PubMed ID: 15688076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 2 diabetes patients' preferences and willingness to pay for lifestyle programs: a discrete choice experiment.
    Veldwijk J; Lambooij MS; van Gils PF; Struijs JN; Smit HA; de Wit GA
    BMC Public Health; 2013 Nov; 13():1099. PubMed ID: 24289831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.